Intravenous albumin shortens the duration of hospitalization for patients with hypoalbuminemia and bleeding peptic ulcers: A pilot study

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Patients with hypoalbuminemia have an increased risk of ulcer rebleeding and longer length of hospitalization. Aims: This study aimed to test whether intravenous albumin can decrease the incidence of rebleeding or shorten the duration of hospitalization in patients with bleeding peptic ulcers and hypoalbuminemia. Methods: Sixty-two patients with bleeding peptic ulcers and Rockall scores ≥6 were prospectively enrolled after having received endoscopic therapy. The enrolled patients were divided into a normal albumin group (serum albumin ≥3 g/dL, n = 39) or an intervention group (<3 g/dL, n = 23) to receive a 3-day course of omeprazole infusion and 25-day oral esomeprazole. Patients (n = 29) with bleeding ulcers and hypoalbuminemia who received the same dose of intravenous and oral omeprazole but did not receive albumin therapy were enrolled from a previous study as the control group. In the intervention group, patients received albumin infusion (10 g q8h) for 1 day (serum albumin levels 2.5-2.9 g/dL) and 2 days (<2.5 g/dL), respectively. Results: The 28-day cumulative rebleeding rates were similar between the intervention group and the control group (39.1 vs. 42.3 %, p = 0.99). The intervention group had a shorter duration of hospitalization (9 vs. 15 days, p = 0.02) than cohort controls. The risk of rebleeding developed after discharge were similar (normal albumin group vs. intervention group vs. control group, 1/5 [20 %] vs. 2/9 [22.2 %] vs. 1/11 [9.1 %], p = 0.7). Conclusions: Albumin administration shortens the duration of hospitalization for patients with peptic ulcer bleeding and hypoalbuminemia, but does not decrease the incidence of rebleeding.

Original languageEnglish
Pages (from-to)3232-3241
Number of pages10
JournalDigestive Diseases and Sciences
Volume58
Issue number11
DOIs
Publication statusPublished - 2013 Nov 1

Fingerprint

Hypoalbuminemia
Peptic Ulcer
Albumins
Hospitalization
Hemorrhage
Omeprazole
Serum Albumin
Control Groups
Ulcer
Esomeprazole
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

@article{3e13a087e85b48feaf63960cdd03cf00,
title = "Intravenous albumin shortens the duration of hospitalization for patients with hypoalbuminemia and bleeding peptic ulcers: A pilot study",
abstract = "Background: Patients with hypoalbuminemia have an increased risk of ulcer rebleeding and longer length of hospitalization. Aims: This study aimed to test whether intravenous albumin can decrease the incidence of rebleeding or shorten the duration of hospitalization in patients with bleeding peptic ulcers and hypoalbuminemia. Methods: Sixty-two patients with bleeding peptic ulcers and Rockall scores ≥6 were prospectively enrolled after having received endoscopic therapy. The enrolled patients were divided into a normal albumin group (serum albumin ≥3 g/dL, n = 39) or an intervention group (<3 g/dL, n = 23) to receive a 3-day course of omeprazole infusion and 25-day oral esomeprazole. Patients (n = 29) with bleeding ulcers and hypoalbuminemia who received the same dose of intravenous and oral omeprazole but did not receive albumin therapy were enrolled from a previous study as the control group. In the intervention group, patients received albumin infusion (10 g q8h) for 1 day (serum albumin levels 2.5-2.9 g/dL) and 2 days (<2.5 g/dL), respectively. Results: The 28-day cumulative rebleeding rates were similar between the intervention group and the control group (39.1 vs. 42.3 {\%}, p = 0.99). The intervention group had a shorter duration of hospitalization (9 vs. 15 days, p = 0.02) than cohort controls. The risk of rebleeding developed after discharge were similar (normal albumin group vs. intervention group vs. control group, 1/5 [20 {\%}] vs. 2/9 [22.2 {\%}] vs. 1/11 [9.1 {\%}], p = 0.7). Conclusions: Albumin administration shortens the duration of hospitalization for patients with peptic ulcer bleeding and hypoalbuminemia, but does not decrease the incidence of rebleeding.",
author = "Cheng, {Hsiu Chi} and Chang, {Wei Lun} and Chen, {Wei Ying} and Tsai, {Yu Ching} and Yeh, {Yi Chun} and Sheu, {Bor Shyang}",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/s10620-013-2821-8",
language = "English",
volume = "58",
pages = "3232--3241",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Intravenous albumin shortens the duration of hospitalization for patients with hypoalbuminemia and bleeding peptic ulcers

T2 - A pilot study

AU - Cheng, Hsiu Chi

AU - Chang, Wei Lun

AU - Chen, Wei Ying

AU - Tsai, Yu Ching

AU - Yeh, Yi Chun

AU - Sheu, Bor Shyang

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Background: Patients with hypoalbuminemia have an increased risk of ulcer rebleeding and longer length of hospitalization. Aims: This study aimed to test whether intravenous albumin can decrease the incidence of rebleeding or shorten the duration of hospitalization in patients with bleeding peptic ulcers and hypoalbuminemia. Methods: Sixty-two patients with bleeding peptic ulcers and Rockall scores ≥6 were prospectively enrolled after having received endoscopic therapy. The enrolled patients were divided into a normal albumin group (serum albumin ≥3 g/dL, n = 39) or an intervention group (<3 g/dL, n = 23) to receive a 3-day course of omeprazole infusion and 25-day oral esomeprazole. Patients (n = 29) with bleeding ulcers and hypoalbuminemia who received the same dose of intravenous and oral omeprazole but did not receive albumin therapy were enrolled from a previous study as the control group. In the intervention group, patients received albumin infusion (10 g q8h) for 1 day (serum albumin levels 2.5-2.9 g/dL) and 2 days (<2.5 g/dL), respectively. Results: The 28-day cumulative rebleeding rates were similar between the intervention group and the control group (39.1 vs. 42.3 %, p = 0.99). The intervention group had a shorter duration of hospitalization (9 vs. 15 days, p = 0.02) than cohort controls. The risk of rebleeding developed after discharge were similar (normal albumin group vs. intervention group vs. control group, 1/5 [20 %] vs. 2/9 [22.2 %] vs. 1/11 [9.1 %], p = 0.7). Conclusions: Albumin administration shortens the duration of hospitalization for patients with peptic ulcer bleeding and hypoalbuminemia, but does not decrease the incidence of rebleeding.

AB - Background: Patients with hypoalbuminemia have an increased risk of ulcer rebleeding and longer length of hospitalization. Aims: This study aimed to test whether intravenous albumin can decrease the incidence of rebleeding or shorten the duration of hospitalization in patients with bleeding peptic ulcers and hypoalbuminemia. Methods: Sixty-two patients with bleeding peptic ulcers and Rockall scores ≥6 were prospectively enrolled after having received endoscopic therapy. The enrolled patients were divided into a normal albumin group (serum albumin ≥3 g/dL, n = 39) or an intervention group (<3 g/dL, n = 23) to receive a 3-day course of omeprazole infusion and 25-day oral esomeprazole. Patients (n = 29) with bleeding ulcers and hypoalbuminemia who received the same dose of intravenous and oral omeprazole but did not receive albumin therapy were enrolled from a previous study as the control group. In the intervention group, patients received albumin infusion (10 g q8h) for 1 day (serum albumin levels 2.5-2.9 g/dL) and 2 days (<2.5 g/dL), respectively. Results: The 28-day cumulative rebleeding rates were similar between the intervention group and the control group (39.1 vs. 42.3 %, p = 0.99). The intervention group had a shorter duration of hospitalization (9 vs. 15 days, p = 0.02) than cohort controls. The risk of rebleeding developed after discharge were similar (normal albumin group vs. intervention group vs. control group, 1/5 [20 %] vs. 2/9 [22.2 %] vs. 1/11 [9.1 %], p = 0.7). Conclusions: Albumin administration shortens the duration of hospitalization for patients with peptic ulcer bleeding and hypoalbuminemia, but does not decrease the incidence of rebleeding.

UR - http://www.scopus.com/inward/record.url?scp=84889570686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889570686&partnerID=8YFLogxK

U2 - 10.1007/s10620-013-2821-8

DO - 10.1007/s10620-013-2821-8

M3 - Article

C2 - 23934414

AN - SCOPUS:84889570686

VL - 58

SP - 3232

EP - 3241

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 11

ER -